Stereotaxis Inc. completes Robocath deal as GenesisX gains first U.S. customer

Stereotaxis Inc. completes Robocath deal as GenesisX gains first U.S. customer
Stereotaxis Inc. revenue tops 1 million

Stereotaxis Inc. reported that its quarterly robotic catheter revenue surpassed 1 million, underlining robust commercial momentum.

During its latest investor call, the company also confirmed the first U.S. purchase of its GenesisX system and announced the initial installations of its Synchrony technology. The completion of the Robocath acquisition further expands Stereotaxis, Inc.'s capabilities in robotic intervention solutions.

Earlier this year, Stereotaxis Inc. presented its GenesisX robot at a St. Louis event focused on heart disease awareness and treatment advances, according to company materials. In Europe, Stereotaxis launched a Genesis robotic electrophysiology lab in Szeged to support medical innovation in Hungary, based on previous disclosures. These initiatives highlight the company's ongoing global deployment of its robotic technologies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.